Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ/Esophageal Adenocarcinoma
NCT05394740Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by National Cancer Center Hospital East. Started Jun 2022; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05394740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394740.